Previous 10 | Next 10 |
2023-10-30 17:35:58 ET More on DBV Technologies Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies For further details see: Equitable Holdings Q3 2023 Earnings P...
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the...
2023-10-16 03:29:26 ET More on DBV Technologies: Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for DBV Technologies For further details see: DBV Technologies appoints Virginie B...
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the a...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 00...
2023-07-31 20:02:16 ET DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call July 31, 2023 17:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer ...
2023-07-31 16:29:01 ET DBV Technologies press release ( NASDAQ: DBVT ): Q2 GAAP EPS of -$0.26. Revenue of $2.3M (+53.3% Y/Y). For further details see: DBV Technologies GAAP EPS of -$0.26, revenue of $2.3M
Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Stud ies and Reports Second Quarter and Half-Year 2023 Financial Results R eceived feedback...
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical com...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR001041...
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to s...
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer Q1 2024 closes with a cash balan...